Tevogen Bio Holdings Inc. is progressing its lead immunotherapy candidate TVGN 489 alongside its innovative AI-powered drug discovery platform, PredicTcell. The company faces significant liquidity constraints and Nasdaq compliance challenges due to a low market capitalization and bid price, posing risks to its listing status. Tevogen's business model relies on clinical-stage advancement and eventual commercialization of immunotherapies enhanced by proprietary AI capabilities, though execution risks remain high. Near-term growth drivers include completion of clinical trials, regulatory submissions, AI platform commercialization, and strategic capital raises.